soul trial oral semaglutide cardiovascular outcomes results 2024 2025 🔴Cardiovascular with by severity of chronic kidney disease in type 2 diabetes: the FLOW trial⤵️ 🔹Semaglutide significantly reduced the risk of CV death/MI/stroke regardless of baseline CKD severity in participants SOUL trial shows oral semaglutide

It helps lighten the skin by inhibiting melanin production, which can reduce dark spots, hyperpigmentation, and uneven skin tone

Until recently, bariatric surgery was considered a first-line treatment for weight loss

Common experiences during week 1-2 include slight changes in appetite patterns, mild nausea that differs from what tirzepatide caused (more constant and less meal-related), and subtle shifts in bowel habits

Taking glutathione with food or reducing the initial dose often helps minimize these effects

A compendium of mucosal molecular characteristics provides novel perspectives on the treatment of ulcerative colitis

Initially approved for T2DM, agents such as liraglutide and semaglutide have shown substantial efficacy in reducing body weight and improving cardiometabolic parameters even in non-diabetic populations [4,5]